Patient P-02693

Synthetic patientMETA-24 · Day 131 · 35–44 · M · baseline S14Open companion preview

Therapy response

Unstable

Tolerance

Stable

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Unstable

Discontinuation risk

92%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 78 ME-01 recommended — Monitoring Escalation ME-01
Day 79 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 79 Patient accepted — Started ME-01 in the companion
Day 82 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 79.

Primary contributors, last 14 days

Inflammatory activity-13
GI instability-9
Treatment adherence-6
Nutritional resilience+5
Toxicity+3

What helped?

Monitoring Escalation ME-01Day 78
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
86% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 55 and rising
- WearableSleep 4.8 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 38/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 53
- WearableHRV 27 ms, trending down
Autonomic recovery ↑45
- WearableResting HR 79 bpm
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 56

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.5 · butyrate capacity 38/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 18 ms
Sleep: 5.4 h
Steps: 5,717
Resting HR: 80 bpm

Daily log: GI score 55, nutritional resilience 40, adherence 44.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02132	61%	S14	SC-12	improved	40
P-02268	59%	S14	GI-04	improved	43
P-02244	54%	S14	GI-04	improved	46
P-02574	54%	S14	ME-01	improved	45
P-02253	51%	S14	NP-02	no change	41
P-02535	50%	S14	SC-12	improved	50
P-02118	49%	S14	GI-04	improved	47
P-02363	49%	S14	GI-04	improved	49
P-02320	48%	S14	NP-02	improved	50
P-02348	48%	S14	GI-04	improved	49
P-02506	47%	S14	SC-12	no change	32
P-02594	47%	S20	—	—	45